Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5824982 | Clinical Therapeutics | 2016 | 9 Pages |
Abstract
These results should be interpreted in light of some study limitations, such as using proportion of days covered as a proxy for adherence, not having clinical data to control for RA severity, and lack of generalizability to all US populations. Given the study findings, both clinicians and other decision makers may want to investigate the potential driving factors of initiation of biologic DMARDs to provide effective RA management and consider patient education programs to enhance medication adherence and persistence to RA medications.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Gilwan PharmD, MS, Jamie C. PhD, Karen PhD, Kristin PhD,